Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $187,864.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the completion of the transaction, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $2,968,149.10. This trade represents a 5.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total transaction of $211,600.00.
• On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total transaction of $170,384.00.
• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total transaction of $54,074.75.
• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10.

Bicara Therapeutics Stock Up 0.8%

Shares of NASDAQ:BCAX opened at $21.75 on Friday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.82 and a beta of -0.57. Bicara Therapeutics Inc. has a 52 week low of $8.48 and a 52 week high of $24.25. The firm has a 50 day moving average of $21.32 and a 200 day moving average of $18.54.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, sell-side analysts expect that Bicara Therapeutics Inc. will post -3.37 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BCAX. The Goldman Sachs Group upped their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Citigroup began coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Wells Fargo & Company upped their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics during the fourth quarter valued at $45,000. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.